Circulating and intestinal regulatory T cells in inflammatory bowel disease: A systemic review and meta-analysis
- PMID: 37615427
- DOI: 10.1080/08830185.2023.2249525
Circulating and intestinal regulatory T cells in inflammatory bowel disease: A systemic review and meta-analysis
Abstract
Regulatory T cells (Tregs) play an important immunosuppressive role in inflammatory bowel disease (IBD). However, findings on the quantitative and functional changes of intestinal and circulating Tregs in patients with IBD are rather contradictory. We therefore conducted a meta-analysis on this issue. The pooled effect was assessed using the standardized mean difference (SMD) with a 95% confidence interval (CI), and subgroup analyses were performed to investigate heterogeneity. This analysis included 764 IBD (402 UC and 362 CD) patients and 341 healthy controls (HCs) pooled from 17 eligible studies. The percentage of circulating Tregs was significantly decreased in active IBD patients compared to HCs (SMD = -0.95, p < 0.001) and inactive IBD patients (SMD = -0.80, p < 0.001). There was no difference in the percentage of circulating Tregs between inactive IBD patients and HCs. The suppressive function of circulating Tregs was impaired in active IBD patients according to limited data (SMD = -0.75, p = 0.02). Besides, the percentage of intestinal Tregs was significantly higher in inflamed regions than in non-inflamed regions (SMD = 0.85, p < 0.001). Our study quantitatively summarized the quantitative and functional changes of Tregs and supported the therapeutic potential of Tregs in IBD. Moreover, additional research into the functions and characteristics of intestinal Tregs in IBD is needed.
Keywords: Immune tolerance; inflammatory bowel disease; meta-analysis; regulatory T cells.
Plain language summary
Inflammatory bowel disease is a group of diseases in which the intestines are repeatedly inflamed. Regulatory T cells are a subset of immune cells that have been found to migrate from the blood and lymphoid tissues into the intestine to act as a suppressor of inflammation in inflammatory bowel disease. However, previous research on changes in the amount and function of regulatory T cells in the blood and intestine of patients with inflammatory bowel disease revealed inconsistent results. Therefore, we used a “meta-analysis” approach to integrate the results of previous studies to obtain an overall picture of Changes in regulatory T cell percentages and function. We found that patients with active inflammatory bowel disease had a lower proportion of blood regulatory T cells and a poorer ability to suppress inflammation compared to healthy individuals. In the intestine of patients with inflammatory bowel disease, a higher proportion of regulatory T cells are found in inflamed sites than in non-inflamed sites. However, compared to other intestinal inflammatory diseases, such as intestinal tuberculosis, patients with inflammatory bowel disease have a lower tendency of elevated proportions of intestinal regulatory T cells. In some ways, our study quantitatively summarized the conflicting results of the quantitative and functional changes of Tregs and supported the therapeutic potential of Tregs in IBD. Moreover, additional research into the functions and characteristics of intestinal Tregs in IBD is needed.
Similar articles
-
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.Cochrane Database Syst Rev. 2021 Apr 19;4(4):CD011535. doi: 10.1002/14651858.CD011535.pub4. Cochrane Database Syst Rev. 2021. Update in: Cochrane Database Syst Rev. 2022 May 23;5:CD011535. doi: 10.1002/14651858.CD011535.pub5. PMID: 33871055 Free PMC article. Updated.
-
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.Cochrane Database Syst Rev. 2017 Dec 22;12(12):CD011535. doi: 10.1002/14651858.CD011535.pub2. Cochrane Database Syst Rev. 2017. Update in: Cochrane Database Syst Rev. 2020 Jan 9;1:CD011535. doi: 10.1002/14651858.CD011535.pub3. PMID: 29271481 Free PMC article. Updated.
-
Vitamin D for the treatment of inflammatory bowel disease.Cochrane Database Syst Rev. 2023 Oct 2;10(10):CD011806. doi: 10.1002/14651858.CD011806.pub2. Cochrane Database Syst Rev. 2023. PMID: 37781953 Free PMC article.
-
Patient education interventions for the management of inflammatory bowel disease.Cochrane Database Syst Rev. 2023 May 4;5(5):CD013854. doi: 10.1002/14651858.CD013854.pub2. Cochrane Database Syst Rev. 2023. PMID: 37172140 Free PMC article.
-
Dietary interventions for recurrent abdominal pain in childhood.Cochrane Database Syst Rev. 2017 Mar 23;3(3):CD010972. doi: 10.1002/14651858.CD010972.pub2. Cochrane Database Syst Rev. 2017. PMID: 28334433 Free PMC article.
Cited by
-
Common mechanisms of Gut microbe-based strategies for the treatment of intestine-related diseases: based on multi-target interactions with the intestinal barrier.Cell Commun Signal. 2025 Jun 18;23(1):288. doi: 10.1186/s12964-025-02299-5. Cell Commun Signal. 2025. PMID: 40528179 Free PMC article. Review.
-
[Cimifugin ameliorates Crohn's disease-like colitis in mice by modulating Th-cell immune balance via inhibiting the MAPK pathway].Nan Fang Yi Ke Da Xue Xue Bao. 2025 Mar 20;45(3):595-602. doi: 10.12122/j.issn.1673-4254.2025.03.17. Nan Fang Yi Ke Da Xue Xue Bao. 2025. PMID: 40159974 Free PMC article. Chinese.
-
Ulcerative colitis: molecular insights and intervention therapy.Mol Biomed. 2024 Oct 10;5(1):42. doi: 10.1186/s43556-024-00207-w. Mol Biomed. 2024. PMID: 39384730 Free PMC article. Review.
-
Discovery and Validation of Ferroptosis-Associated Genes of Ulcerative Colitis.J Inflamm Res. 2024 Jul 9;17:4467-4482. doi: 10.2147/JIR.S463042. eCollection 2024. J Inflamm Res. 2024. PMID: 39006497 Free PMC article.
References
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources